source
- Cytokinetics reports Phase 3 success for Myqorzo but shares tumble as investors weigh market impactAt the European Society of Cardiology meeting, Cytokinetics presented Phase 3 data for Myqorzo in non‑obstructive hypertrophic cardiomyopathy, showing benefit in both forms of the disease and disti…
- Novartis and Bristol Myers pause autoimmune CAR-T trials after safety concernsNovartis announced a temporary hold on its personalized CAR-T therapy rap-cel after three patients experienced immune effector cell-associated hemophagocytic syndrome, a rare and potentially life-t…